Roche Announces Positive Phase III Results for Inavolisib Combination in Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation

Roche in the NEWS
From Basel, today, December 5, 2023 - Roche (RHHBY) announced positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance®) and fulvestrant as a potential first-line treatment option for people with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.